Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)

In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Quest Diagnostics (DGX – Research Report), with a price target of $145.00. The company’s shares closed yesterday at $139.50.

Westenberg covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Zoetis, and Natera. According to TipRanks, Westenberg has an average return of -2.6% and a 39.10% success rate on recommended stocks.

In addition to Piper Sandler, Quest Diagnostics also received a Hold from Barclays’s Stephanie Davis in a report issued on April 25. However, on April 24, Bank of America Securities assigned a Buy rating to Quest Diagnostics (NYSE: DGX).

The company has a one-year high of $143.16 and a one-year low of $117.60. Currently, Quest Diagnostics has an average volume of 1.05M.

Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DGX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quest Diagnostics (DGX) Company Description:

Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.